NovoCure Limited
Healthcare · EUR · F
Price
€15.231
Cap
€2.07B
Earnings
—
30d Trend
+50.1%
91% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 39×Macro 0.99 (−1%)=39
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
6-9 month momentum thesis — strong trend with confirmation
BRAIN47'S ASSESSMENT
I rate NovoCure Limited at 39/100 — a WEAK reading on the Brain47 Signal. The strongest factor is technical at 60/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
+44.6%
3 MONTHS
+26.2%
12 MONTHS
-11.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month momentum thesis — strong trend with confirmation. Technical (60) and Quality (50) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 91%. I classify this as a speculative position — elevated volatility at 91% and asymmetric payoff potential define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.